US trials go-ahead for Nitinol septal occluder:
This article was originally published in Clinica
Executive Summary
The FDA has agreed to trials of Nitinol's Cardioseal septal occluder. The device is a heart implant designed to close transient holes (patent foramen ovale) in the atrial septum and is being used routinely at some European hospitals, said Nitinol. The US trials will begin at up to 15 sites later in the spring, after some protocol changes demanded by the FDA.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.